Patients with current deep vein thrombosis or deep vein thrombosis within the past  months are not eligible
STEP I: Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but must be willing to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or are currently receiving therapeutic or prophylactic doses of anticoagulants.
History of deep vein thrombosis and/or pulmonary embolus within  months of study entry
Presence of deep vein thrombosis based on screening lower extremity Doppler ultrasonography.
History of blood clots, pulmonary embolism, or deep vein thrombosis unless on adequate anticoagulant therapy as determined by the treating investigator (subject must be on stable dose for  weeks).
Patient must not have any thromboembolic event (deep vein thrombosis or pulmonary embolism) less than  weeks prior to enrollment
Deep vein thrombosis or pulmonary embolism =<  weeks before first dose of protocol-indicated treatment, unless adequately treated and stable.\r\n* Patients receiving therapeutic non-coumarin anticoagulation are eligible, provided they are on a stable dose (per investigator judgment) of anticoagulant.
A diagnosis of deep vein thromboses in the preceding four weeks of study enrollment.
Have been treated for a deep vein thrombosis, pulmonary embolism, myocardial infarction, or ischemic stroke within the past  months (may be extended to  year if medically indicated per physician discretion).
History of symptomatic deep vein thrombosis or pulmonary embolism within  months of enrollment.
have a history of venous thromboembolism, including deep vein thrombosis, pulmonary embolism or retinal vein thrombosis, unless currently on anticoagulant therapy;
History of symptomatic deep vein thrombosis or pulmonary embolism within  months of enrollment
Prior or concurrent deep vein thrombosis or pulmonary embolism
Patients who have a history of deep vein thrombosis or pulmonary embolus and are stable on anticoagulation for >  month are eligible
History of deep vein thrombosis or pulmonary embolism within  month of anticipated starting of axitinib
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within  days of\r\nstudy enrollment)
Myocardial infarction, uncontrolled angina, congestive heart failure, or cerebrovascular accident within previous  months; subjects with a history of deep vein thrombosis or pulmonary embolism, at provider discretion
Any of the following in the previous  months: deep vein thrombosis or symptomatic pulmonary embolism
History of deep vein thrombosis or pulmonary embolism requiring systemic anticoagulation within  months before enrollment
significant cardiovascular disease within the last  months: including myocardial infarction, unstable angina, congestive heart failure, ongoing arrhythmias of Grade >  , thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism). Chronic stable atrial fibrillation on stable anticoagulant therapy is allowed.
Patients with a recent history of deep vein thrombosis or pulmonary embolus, in the six months prior to enrollment are not eligible for this study
Patients with any of the following within  months of enrollment: deep vein thrombosis, pulmonary embolus, myocardial infarction, cerebrovascular accident, unexplained loss of consciousness
Deep vein thrombosis or pulmonary embolism within  months of study entry
History of deep vein thrombosis and/or pulmonary embolism within  weeks of enrollment.
Deep vein thrombosis or pulmonary embolism =<  weeks before first dose of protocol-indicated treatment, unless adequately treated and stable
History of vascular disease (e.g. deep vein thrombosis, stroke)
Acute deep vein thrombosis or clinically relevant pulmonary embolism, not stable for at least  weeks prior to first IMP administration.
Patients must not have a history of prior stroke, transient ischemic attack (TIA), pulmonary embolism, or untreated deep vein thrombosis\r\n* NOTE: Patients may be eligible if they have received at least  months of anticoagulation for a deep vein thrombosis
History of deep vein thrombosis or pulmonary embolism within  months of screening; patients who are currently taking anticoagulation therapy for a prior history (>  months from screening) of thrombosis may still be eligible
History of blood clots, pulmonary embolism, or deep vein thrombosis in previous  months unless controlled by anticoagulant treatment
Prior history of a major thrombotic event, such as pulmonary emboli, deep vein thrombosis or stroke, as assessed by the investigator, or history of an asparaginase associated serious hemorrhage or thrombus requiring anticoagulation therapy
History of pulmonary embolus and/or substantial deep vein thrombosis
Patients may have a history of current or previous deep vein thrombosis or pulmonary embolism but are required to take some form of anti-coagulation as prophylaxis if they are not currently on full-dose anticoagulation
Has had within the past  months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (NCI CTCAE Grade  or ), chronic liver disease (meeting criteria for Child-Pugh Class B or C), or organ transplantation.
Has a history of deep vein thrombosis or pulmonary embolism within  months of screening.
History of symptomatic deep vein thrombosis or pulmonary embolism within  months of enrollment.
Conditions contraindicated to progesterone treatment (including, but not limited to, thrombophlebitis, deep vein thrombosis, pulmonary embolus, clotting or bleeding disorders, heart disease, diabetes, history of stroke, allergy to peanuts, hypersensitive to progesterone and liver dysfunction)
Known, existing uncontrolled coagulopathy; patients who have had a venous thromboembolic event (e.g., pulmonary embolism or deep vein thrombosis) requiring anticoagulation are eligible IF: they are appropriately anticoagulated and have not had a grade  or greater bleeding episode in the  weeks before day 
Has a history of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment (patient must be on stable dose for  weeks).
History of blood clots, pulmonary embolism, or deep vein thrombosis unless controlled by anticoagulant treatment.
Have had a new pulmonary embolism, extremity deep venous thromboembolism, or portal vein thrombosis within  months of study enrollment (any thrombosis within  months of study enrollment must be approved by the protocol chair and/or medical monitor)
In past  months: deep vein thrombosis or pulmonary embolism
Known history of deep vein thrombosis or pulmonary embolus except in patients where the cause was directly related to foreign body implants, i.e. central venous catheters, portacaths, etc.
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within  days of study enrollment)
Venous thromboembolic events (e.g., deep vein thrombosis or pulmonary embolism) within  months of screening
Candidates may have a history of deep vein thrombosis, pulmonary embolism, and/or cerebrovascular accident, or require concomitant systemic anticoagulation, if otherwise deemed to be suitable for RP
Thromboembolic events (e.g., deep vein thrombosis, pulmonary embolism, arterial thrombosis) within  months prior to enrollment.
Documented deep vein thrombosis within  year before enrollment on the study, except if upper arm thrombosis related to central venous catheters, within  months before enrollment on the study
Deep vein thrombosis in the preceding  months.
Unstable pulmonary embolism, deep vein thrombosis, or other significant arterial/venous thromboembolic event =<  days before enrollment
Patients with active pulmonary embolism or deep vein thrombosis (diagnosed within  days of study enrollment)
Pulmonary embolism, deep vein thrombosis, or other significant venous event =<  weeks before enrollment
Evidence of hepatic vein invasion or caval thrombosis
Has had within the past  months the occurrence of one or more of the following events: myocardial infarction, cerebrovascular accident, deep vein thrombosis, pulmonary embolism, hemorrhage (CTC Grade  or ), chronic liver disease (meeting criteria for Child-Pugh Class B or C), a second active malignancy (excluding basal cell carcinoma and cervical carcinoma in situ), organ transplantation.
Have a history of deep vein thrombosis, pulmonary embolism, or any other significant thromboembolic event during the  months prior to receiving study drugs.
Occurrence of deep vein thrombosis within  weeks, prior to study entry
Thromboembolic events (eg, deep vein thrombosis, pulmonary embolism, arterial thrombosis) within  months of screening
Deep vein thrombosis diagnosed within  months
History within  months of deep vein thrombosis, pulmonary embolism, or stroke
Patients with a history of deep vein thrombosis or thromboembolism within <  months prior to starting study treatment
Prior or concurrent deep vein thrombosis or pulmonary embolism
No thrombotic event within  months (deep vein thrombosis, pulmonary embolism) of registration for protocol therapy.
History of deep vein thrombosis or pulmonary embolism.
Patients with a history of deep vein thrombosis or thromboembolism within <  months prior to starting study treatment
Patients who have had a deep vein thrombosis or pulmonary embolus within the past  months are eligible if they are on stable therapeutic anticoagulation
Suspected or diagnosed deep vein thrombosis or painful foot neuropathy.
Active deep vein thrombosis in the treatment extremity
History of thrombosis, deep vein thrombosis, pulmonary emboli, or embolic stroke AND have not been stable on anticoagulants within the past  months; local central line thrombosis is allowed
Within the past  months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosis
CONTROL (HEALTHY) GROUP: Within the past  months:\r\n* Acute pulmonary embolus\r\n* Deep vein thrombosis
Conditions that could cause swelling (e.g., pregnancy, congestive heart failure, chronic/acute renal disease, cor pulmonale, nephrotic syndrome, nephrosis, liver failure or cirrhosis, pulmonary edema, and thrombophlebitis, or deep vein thrombosis in arms
History of blood clots (i.e. pulmonary embolism, deep vein thrombosis [DVTs])
History of deep vein thrombosis or pulmonary embolism within  weeks of first study dose
History of: Thrombophelitis, Deep vein thrombosis, Pulmonary embolus, Clotting disorder, Bleeding disorder, Heart disease, Diabetes, Stroke, Peanut allergy, Liver dysfunction, Hypersensitivity to progesterone
Patients with thrombosis within the splenic vein
Symptomatic deep vein thrombosis or pulmonary embolism within last  months
No thrombotic event within  months (deep vein thrombosis, pulmonary embolism) of starting IFN gamma
History of deep vein thrombosis or pulmonary embolism.
Participants requires the use of warfarin (use in prophylactic doses [example, deep vein thrombosis prophylaxis]) is allowed.
